

THE PRIMARY CARE COMPANION FOR CNS DISORDERS

Supplementary Material

Article Title: A Review of L-Methylfolate as Adjunctive Therapy in the Treatment of Major Depressive

Disorder

Author(s): Vladimir Maletic, MD; Richard Shelton, MD; and Valerie Holmes, MD

DOI Number: https://doi.org/10.4088/PCC.22nr03361

List of Supplementary Material for the article


1. Supplementary Figure 1

2. Supplementary Table 1

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Figure 1. Impact of Depression* on Quality of Life^{†1}



LMF, L-methylfolate; PHQ-9, Patient Health Questionnaire.

*Based on depression symptoms reported in PHQ-9 questionnaire.

†Quality of life measured as self-reported difficulty of home, work, and social functions.

Supplementary Table 1. Pooled HAM-D Treatment Effects in the First Post Hoc

Analysis of the 2 Randomized, Double-Blind, Parallel-Sequential Trials²

Variable	N	Pooled Mean Change vs Placebo	95% Confidence Interval	P Value	Pooled Effect Size
SAM/SAH ratio					
≥ 2.71	36	0.07	-3.33 to 3.48	0.966	0.01
< 2.71	37	-4.57	-7.73 to -1.41	0.005	-0.75
HsCRP					
≥ 2.25 mg/L	37	-3.61	-7.23 to 0.002	0.050	-0.50
< 2.25 mg/L	36	-2.29	-5.47 to 0.89	0.158	-0.36
4-HNE					
≥ 3.28 ug/mL	37	-4.55	-7.61 to -1.50	0.003	-0.74
< 3.28 ug/mL	36	-0.11	-3.67 to 3.46	0.953	0.01

HsCRP, high-sensitivity C-reactive protein; 4-HNE, 4-hydroxynonenal; LMF, L-methylfolate; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine.

References

- 1. Shelton RC, Sloan Manning J, Barrentine LW, Tipa EV. Assessing effects of I-methylfolate in depression management: results of a real-world patient experience trial. Prim Care Companion CNS Disord 2013;15.
- 2. Papakostas GI, Shelton RC, Zajecka JM, et al. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry 2014;75:855-63.